NIH Workshop on Psychedelics as Therapeutics

Washington, D.C., United States,
To learn what does Science can tell about the gaps, challenges, and opportunities on psychedelics as therapeutics, the US National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), and National Institute on Alcohol Abuse and Alcoholism (NIAAA) will host a virtual and free workshop on January 12 and 13, 2022.

Ibogaine Treatment Outcomes for Opioid Dependence from a Twelve-Month Follow-Up Observational Study

Geoffrey E. Noller, Chris M. Frampton & Berra Yazar-Klosinski (2018) Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study, The American Journal of Drug and Alcohol Abuse, 44:1, 37-46, DOI: 10.1080/00952990.2017.1310218
Publication Date


Background: The psychoactive indole alkaloid ibogaine has been associated with encouraging treatment outcomes for opioid dependence. The legal status of ibogaine in New Zealand provides a unique opportunity to evaluate durability of treatment outcomes.